Merck
  • Home
  • Search Results
  • Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

International ophthalmology (2011-08-19)
Maria Gkika, Georgios Labiris, Vassilios Kozobolis
ABSTRACT

Corneal collagen cross-linking (CXL) using riboflavin and ultraviolet-A irradiation is a common method of tissue stabilization and has been developed primarily to address the need of treating keratoconus. CXL's promising results on keratoconus indicated that it might be effective in other corneal diseases as well. This new treatment promises a slowing effect on the progression of these diseases and its initial results show that it is safe and reasonably curative. The purpose of this review is to critically evaluate this treatment, to explore its benefits, to highlight its limitations in terms of efficacy and long-term safety and finally to identify areas for future research in this topic with a significant potential to change the way we treat our patients. In addition, in this unbiased review we try to bring together all the scientific information from both laboratory and clinical trials that have been conducted during recent years and to review the most recent publications regarding the therapeutic indications of CXL.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(−)-Riboflavin, from Eremothecium ashbyii, ≥98%
Sigma-Aldrich
(−)-Riboflavin, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Sigma-Aldrich
(−)-Riboflavin, meets USP testing specifications
Supelco
Riboflavin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Riboflavin (B2), analytical standard
Riboflavin for peak identification, European Pharmacopoeia (EP) Reference Standard